Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Number Needed to Treat: 66 for One Major Cardiovascular Event

A review of 21 trials estimated how many people would need treatment to prevent one additional cardiovascular event.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team6 min read
People treated per additional event preventedmajor cardiovascular event66one death, any cause121cardiovascular death170Mean follow-up across trials: 2.4 years

The number needed to treat estimates how many people receive treatment for one additional outcome to be prevented compared with a control group. The guide to what the SELECT trial counted as a cardiovascular event gives an example. A combined outcome includes events beyond heart attacks.[1]

What the pooled trials found

The review included 21 randomized trials of eight medications, including tirzepatide. Average follow-up across the trials was 2.4 years. The estimated number needed to treat was 66 for a trial-defined major cardiovascular event (incidence rate ratio 0.87, 95% CI 0.83–0.91). It was 121 for death from any cause and 170 for cardiovascular death.[1]

The same review found more gastrointestinal and gallbladder disorders in the treatment groups. The separate analysis of gallstones and reflux in randomized trials reports how those outcomes changed in absolute terms. They are different outcomes from those used to calculate the cardiovascular estimate.[1]

Why baseline risk and follow-up matter

The authors calculated these figures from absolute risk differences. One fewer event per 66 people compares the total number of events between groups. It does not identify which people benefited or capture other outcomes. A lower starting risk can mean a smaller absolute benefit even when the relative effect is the same.[1]

Participants included people with cardiovascular disease or risk factors such as diabetes, obesity, or kidney disease. Different studies used different follow-up periods and definitions of cardiovascular events. The pooled result should be read with those differences in mind.[1]

Frequently asked

What does a number needed to treat of 66 mean?
In the pooled trial populations, the authors estimated one fewer major cardiovascular event per 66 people assigned treatment compared with control over the follow-up studied.
Does the estimate of 66 apply to an individual?
It describes a group and depends on the outcome, baseline risk, and length of follow-up. It cannot predict an individual’s benefit.

Sources

  1. [1] Galli M, et al. (2025). Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Journal of the American College of Cardiology. PMID 40892610

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence